

Santiago Bonanad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6410612/publications.pdf>

Version: 2024-02-01

79
papers

1,759
citations

394286

19
h-index

302012

39
g-index

83
all docs

83
docs citations

83
times ranked

2290
citing authors

#	ARTICLE	IF	CITATIONS
1	A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. <i>New England Journal of Medicine</i> , 2016, 374, 2054-2064.	13.9	414
2	Cytogenetic risk stratification in chronic myelomonocytic leukemia. <i>Haematologica</i> , 2011, 96, 375-383.	1.7	226
3	Choosing outcome assessment tools in haemophilia care and research: a multidisciplinary perspective. <i>Haemophilia</i> , 2017, 23, 11-24.	1.0	63
4	Adherence to prophylaxis and quality of life in children and adolescents with severe haemophilia A. <i>Haemophilia</i> , 2015, 21, 458-464.	1.0	51
5	Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale. <i>Journal of Geriatric Oncology</i> , 2015, 6, 353-361.	0.5	51
6	Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction. <i>Leukemia Research</i> , 2015, 39, 296-306.	0.4	50
7	Influence of Methylene Blue Photoinactivation Treatment on Coagulation Factors from Fresh Frozen Plasma, Cryoprecipitates and Cryosupernatants. <i>Vox Sanguinis</i> , 2000, 79, 156-160.	0.7	43
8	Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 39-43.	1.9	39
9	Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm. <i>Thrombosis and Haemostasis</i> , 2016, 115, 40-50.	1.8	36
10	Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by next-generation sequencing of 480 patients. <i>Haematologica</i> , 2017, 102, 2005-2014.	1.7	35
11	Use of Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) for Carcinoembryonic Antigen, Cytokeratin 19, and Maspin in the Detection of Tumor Cells in Leukapheresis Products from Patients with Breast Cancer: Comparison with Immunocytochemistry. <i>Stem Cells and Development</i> , 1999, 8, 53-61.	1.0	34
12	Minimal illegitimate levels of cytokeratin K19 expression in mononucleated blood cells detected by a reverse transcription PCR method (RT-PCR). <i>Clinica Chimica Acta</i> , 1997, 263, 105-116.	0.5	33
13	Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A. <i>Thrombosis Research</i> , 2019, 174, 151-162.	0.8	27
14	Prolonged molecular remission after PML/RAR \pm -positive autologous peripheral blood stem cell transplantation in acute promyelocytic leukemia: is relevant pretransplant minimal residual disease in the graft?. <i>Leukemia</i> , 1998, 12, 992-995.	3.3	24
15	Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA Study. <i>International Journal of Clinical Practice</i> , 2006, 60, 518-525.	0.8	24
16	Increase of Neutrophil Activation Markers in Venous Thrombosis—Contribution of Circulating Activated Protein C. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5651.	1.8	24
17	Safety and Effectiveness of Progressive Moderate-to-Vigorous Intensity Elastic Resistance Training on Physical Function and Pain in People With Hemophilia. <i>Physical Therapy</i> , 2020, 100, 1632-1644.	1.1	24
18	Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 778-790.	1.9	23

#	ARTICLE	IF	CITATIONS
19	The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome. <i>Leukemia Research</i> , 2012, 36, 287-292.	0.4	22
20	HemoKinect: A Microsoft Kinect V2 Based Exergaming Software to Supervise Physical Exercise of Patients with Hemophilia. <i>Sensors</i> , 2018, 18, 2439.	2.1	22
21	Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2016, 34, 3284-3292.	0.8	20
22	Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. <i>International Journal of Molecular Sciences</i> , 2017, 18, 837.	1.8	19
23	Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score. <i>Leukemia Research</i> , 2015, 39, 52-57.	0.4	18
24	Further psychometric validation of the GAH scale: Responsiveness and effect size. <i>Journal of Geriatric Oncology</i> , 2017, 8, 211-215.	0.5	18
25	Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 528-541.	1.0	18
26	Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate [®]): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup. <i>Clinical Pharmacokinetics</i> , 2020, 59, 245-256.	1.6	18
27	Novel investigations on the protective role of the <i>FVIII</i> / <i>VWF</i> complex in inhibitor development. <i>Haemophilia</i> , 2014, 20, 2-16.	1.0	17
28	HLA-DQA, -DQB AND -DRB ALLELE CONTRIBUTION TO NARCOLEPSY SUSCEPTIBILITY. <i>International Journal of Immunogenetics</i> , 1997, 24, 409-421.	1.2	16
29	Relationships between antithrombin activity, anticoagulant efficacy of heparin therapy and perioperative variables in patients undergoing cardiac surgery requiring cardiopulmonary bypass. <i>Perfusion (United Kingdom)</i> , 2011, 26, 487-495.	0.5	16
30	Home-delivered ultrasound monitoring for home treatment of haemarthrosis in haemophilia A. <i>Haemophilia</i> , 2015, 21, e147-50.	1.0	16
31	Physical Activity Monitoring and Acceptance of a Commercial Activity Tracker in Adult Patients with Haemophilia. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 3851.	1.2	16
32	Moderate and severe haemophilia in Spain: An epidemiological update. <i>Haemophilia</i> , 2018, 24, e136-e139.	1.0	14
33	$\hat{I}\pm 2$ -Macroglobulin Is a Significant In Vivo Inhibitor of Activated Protein C and Low APC: $\hat{I}\pm 2$ M Levels Are Associated with Venous Thromboembolism. <i>Thrombosis and Haemostasis</i> , 2018, 47, 630-638.	1.8	13
34	Unraveling the effect of silent, intronic and missense mutations on <i>VWF</i> splicing: contribution of next generation sequencing in the study of mRNA. <i>Haematologica</i> , 2019, 104, 587-598.	1.7	13
35	Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS [®]). <i>American Journal of Hematology</i> , 2017, 92, 614-621.	2.0	12
36	Effect of radiosynoviorthesis on the progression of arthropathy and haemarthrosis reduction in haemophilic patients. <i>Haemophilia</i> , 2017, 23, e497-e503.	1.0	12

#	ARTICLE	IF	CITATIONS
37	<scp>FVIII</scp> inhibitor development according to concentrate: data from the <scp>EUHASS</scp> registry excluding overlap with other studies. Haemophilia, 2016, 22, e36-8.	1.0	11
38	Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes. Modern Pathology, 2016, 29, 1541-1551.	2.9	11
39	Quantification of physical activity in adult patients with haemophilic arthropathy in prophylaxis treatment using a fitness tracker. Haemophilia, 2018, 24, e28-e32.	1.0	11
40	Upper-Body Exercises With External Resistance Are Well Tolerated and Enhance Muscle Activity in People With Hemophilia. Physical Therapy, 2019, 99, 411-419.	1.1	11
41	Joint status in Spanish haemophilia B patients assessed using the Haemophilia Early Arthropathy Detection with Ultrasound (HEADâ€US) score. Haemophilia, 2019, 25, 144-153.	1.0	11
42	Clotting factors in cryoprecipitate and cryo-supernatant prepared from MB-treated fresh plasma. Transfusion, 2000, 40, 493-493.	0.8	10
43	Inhibitor development after switching of <scp>FVIII</scp> concentrate in multitransfused patients with severe haemophilia A. Haemophilia, 2014, 20, 624-629.	1.0	10
44	Electromyographic and Safety Comparisons of Common Lower Limb Rehabilitation Exercises for People With Hemophilia. Physical Therapy, 2020, 100, 116-126.	1.1	9
45	Crossâ€sectional comparative study of pharmacokinetics and efficacy between sucroseâ€formulated recombinant factor VIII (Kogenate ^{Â®}) and BAY 81â€8973 (Kovaltry ^{Â®}) in patients with severe or moderate haemophilia A in prophylaxis. Haemophilia, 2019, 25, e215-e218.	1.0	9
46	Effects of a nonâ€pharmacological approach for chronic pain management in patients with haemophilia: efficacy of cognitiveâ€behavioural therapy associated with physiotherapy. Haemophilia, 2021, 27, e357-e367.	1.0	9
47	Identification of 58 Mutations (26 Novel) in 94 of 109 Symptomatic Spanish Proband with Protein C Deficiency. Thrombosis and Haemostasis, 2019, 119, 1409-1418.	1.8	8
48	Clinical and molecular characterization by next generation sequencing of Spanish patients affected by congenital deficiencies of fibrinogen. Thrombosis Research, 2019, 180, 115-117.	0.8	8
49	Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients. Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46, 427-438.	0.8	8
50	Ultrasound evaluation of joint damage and disease activity in adult patients with severe haemophilia A using the HEADâ€US system. Haemophilia, 2021, 27, 479-487.	1.0	8
51	Haemo<scp>PREF</scp>: Further evaluation of patient perception and preference for treatment in a real world setting. Haemophilia, 2017, 23, 884-893.	1.0	7
52	GuÃa prÃctica de tratamiento urgente de la microangiopatÃa trombÃtica. Medicina ClÃnica, 2018, 151, 123.e1-123.e9.	0.3	7
53	The factor VIII treatment history of nonâ€severe hemophilia A: COMMENT. Joint damage in adult patients with mild or moderate hemophilia A evaluated with the HEADâ€US system. Journal of Thrombosis and Haemostasis, 2021, 19, 2638-2641.	1.9	7
54	Platelet function in malignant hematological disorders. Current Opinion in Oncology, 2015, 27, 522-531.	1.1	6

#	ARTICLE	IF	CITATIONS
55	Role of multimeric analysis of von Willebrand factor (VWF) in von Willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project. PLoS ONE, 2018, 13, e0197876.	1.1	6
56	Pilot evaluation of home delivery programme in haemophilia. Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 822-828.	0.7	6
57	Assessment of Kinect V2 for elbow range of motion estimation in people with haemophilia using an angle correction model. Haemophilia, 2019, 25, e165-e173.	1.0	6
58	P030 Prognostic impact on survival of an unsuccessful conventional cytogenetic study in patients with myelodysplastic syndromes (MDS). Leukemia Research, 2009, 33, S75-S76.	0.4	5
59	A simplified assay for the quantification of circulating activated protein C. Clinica Chimica Acta, 2016, 459, 101-104.	0.5	4
60	Clinical, pharmacokinetic and economic analysis of the first switch to an extended half-life factor IX (albutrepenonacog alfa, rFIX-FP) in Spain. BMJ Case Reports, 2020, 13, e234142.	0.2	4
61	Factor XIII deficiency in two Spanish families with a novel variant in gene F13A1 detected by next-generation sequencing; symptoms and clinical management. Journal of Thrombosis and Thrombolysis, 2020, 50, 686-688.	1.0	4
62	Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients. Thrombosis Research, 2021, 205, 99-105.	0.8	4
63	Feasibility, safety and muscle activity during flywheel vs traditional strength training in adult patients with severe haemophilia. Haemophilia, 2021, 27, e102-e109.	1.0	3
64	A New Method for Phenotyping Red Blood Cells Using Microplates. Vox Sanguinis, 1999, 77, 143-148.	0.7	3
65	CYTOKINES AND PLATELET ACTIVATION IN STORED POOLED BUFFY COAT-DERIVED PLATELET CONCENTRATES; THE ISSUE OF TRANSFUSIONAL REACTIONS. British Journal of Haematology, 1996, 95, 755-756.	1.2	2
66	Practice guidelines for the emergency treatment of thrombotic microangiopathy. Medicina Clínica (English Edition), 2018, 151, 123.e1-123.e9.	0.1	2
67	Next generation sequencing in bleeding disorders: two novel variants in the F5 gene (Valencia-1 and Tj ETQq1 1 0.784314 rgBT /Over 48, 674-678.	1.0	2
68	Adherence to prophylaxis in adult patients with severe haemophilia A. Haemophilia, 2020, 26, 800-808.	1.0	2
69	Unraveling the Influence of Common von Willebrand factor variants on von Willebrand Disease Phenotype: An Exploratory Study on the Molecular and Clinical Profile of von Willebrand Disease in Spain Cohort. Thrombosis and Haemostasis, 2020, 120, 437-448.	1.8	2
70	Comparison of Two Reverse Transcription-Polymerase Chain Reaction Methods for Detection of AML1/ETO Rearrangement in the M2 Subtype of Acute Myeloid Leukaemia. Clinical Chemistry and Laboratory Medicine, 1998, 36, 137-42.	1.4	1
71	Quality of thawed plasma inactivated with methylene blue after 48-hour storage. Transfusion and Apheresis Science, 2015, 52, 141-142.	0.5	1
72	Predictive factors of immune tolerance treatment response in severe haemophilia A patients with inhibitors: A real-world report from a single centre, mixed retrospective-prospective long-term study. Haemophilia, 2019, 25, e97-e100.	1.0	1

#	ARTICLE	IF	CITATIONS
73	Signal transducer and activator of transcription 3 (STAT3) phosphorylation regulates thromboxane A 2 receptor activity in human platelets. <i>British Journal of Haematology</i> , 2020, 188, e39-e42.	1.2	1
74	Costs of the management of hemophilia A with inhibitors in Spain. <i>Global & Regional Health Technology Assessment</i> , 0, 8, 35-42.	0.2	1
75	Incidencia de infección por hepatitis C en donantes de cabezas femorales para el banco de tejidos. <i>Revista Espanola De Salud Publica</i> , 1998, 72, 267-271.	0.3	1
76	P029 Prognostic relevance of specific chromosomal abnormalities in chronic myelomonocytic leukemia. <i>Leukemia Research</i> , 2009, 33, S74-S75.	0.4	0
77	Type 2N VWD: Conclusions from the Spanish PCMâ€VWâ€ES project. <i>Haemophilia</i> , 2021, 27, 1007-1021.	1.0	0
78	Cerebral calcium embolism. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, e04962.	0.2	0
79	ABO group-based strategy for inventory management of methylene blue-treated thawed plasma in a blood bank. <i>Transfusion and Apheresis Science</i> , 2022, , 103438.	0.5	0